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Background: Overexpression of transketolase-like 1 protein TKTL1 in cancer cells has been reported to correlate
with enhanced glycolysis and lactic acid production. Furthermore, enhanced TKTL1 expression was put into context
with resistance to chemotherapy and ionizing radiation. Here, a panel of human malign and benign cells, which
cover a broad range of chemotherapy and radiation resistance as well as reliance on glucose metabolism, was analyzed
in vitro for TKTL1 expression.
Methods: 17 malign and three benign cell lines were characterized according to their expression of TKTL1 on the
protein level with three commercially available anti-TKTL1 antibodies utilizing immunohistochemistry and Western blot,
as well as on mRNA level with three published primer pairs for RT-qPCR. Furthermore, sensitivities to paclitaxel, cisplatin
and ionizing radiation were assessed in cell survival assays. Glucose consumption and lactate production were quantified
as surrogates for the “Warburg effect”.
Results: Considerable amounts of tktl1 mRNA and TKTL1 protein were detected only upon stable transfection
of the human embryonic kidney cell line HEK293 with an expression plasmid for human TKTL1. Beyond that,
weak expression of endogenous tktl1 mRNA was measured in the cell lines JAR and U251. Western blot
analysis of JAR and U251 cells did not detect TKTL1 at the expected size of 65 kDa with all three antibodies
specific for TKTL1 protein and immunohistochemical staining was observed with antibody JFC12T10 only. All other
cell lines tested here revealed expression of tktl1 mRNA below detection limits and were negative for TKTL1 protein.
However, in all cell lines including TKTL1-negative HEK293-control cells, antibody JFC12T10 detected multiple proteins
with different molecular weights. Importantly, JAR and U251 did neither demonstrate an outstanding production of
lactic acid nor increased resistance against chemotherapeutics or to ionizing radiation, respectively.
Conclusion: Using RT-qPCR and three different antibodies we observed only exceptional occurrence of TKTL1 in
a panel of malignant human cell lines in vitro. The presence of TKTL1 was unrelated to either the rate of glucose
consumption/lactic acid production or resistance against chemo- and radiotherapy.
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Transketolase (TKT; EC: 2.2.1.1) is a thiamine-dependent
key enzyme involved in the non-oxidative branch of the
pentose phosphate pathway (PPP), which catalyzes the
transfer of a 2-carbon fragment (H2C(OH)-CO-) from
xylulose 5-phosphate to either ribose 5-phosphate (to form
sedoheptulose 7-phosphate) or erythrose 4-phosphate* Correspondence: frak057@mail.uni-wuerzburg.de
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creativecommons.org/publicdomain/zero/1.0/(to form fructose 6-phosphate). TKT, together with the
transaldolase enzyme, reversibly links the PPP to glycolysis
[1,2]. Both pathways occur exclusively in the cytosol and,
depending on the metabolic demands of the cell, the PPP
provides precursors for biosynthetic reactions or metabolites
for glycolysis [3]. An altered PPP was reported to be
involved in carcinogenesis and resistance to chemothera-
peutic intervention, although the underlying mechanisms
remain to be elucidated in more detail [4].
An alteration in the activity of the TKT enzyme was
proposed to be responsible for the thiamine-deficiencys article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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[5]. A genomic-wide screen revealed a new gene identified
in embryonic brain and heart tissue, located on the Xq28
region next to genes of cancer/testis antigens (CTA). This
gene was termed TKT-related (TKR) gene [6]. The TKR
gene corresponds to an open reading frame of 540 codons
with a nucleotide sequence demonstrating 60-67%
homology to the highly conserved TKT gene of humans,
mice and other species. TKR gene was assumed to be a
pseudogene based on the presence of a premature
stop-codon within the predicted open reading frame
and a deletion of exon 3 of TKT, which encodes for
amino acids important for the biochemical function
of the TKT enzyme [7]. Later the TKR gene has been
renamed transketolase-like 1 (TKTL1) gene; together with
TKT and TKTL2, another TKT-like gene, it represents
one of three isoforms of TKT [2,7,8]. Of note, the TKTL1
gene has been found especially in human testis tissue
during germ cell maturation and in corresponding
seminal plasma of fertile donors, a finding consistent with
the CTA location of the gene [9,10].
The commercially available monoclonal antibody
JFC12T10 that recognizes the C-terminal fragment of
recombinant TKTL1 protein [7] was used for immu-
nohistochemistry and Western blot studies on a large
panel of human tissues and cell lines to analyze TKTL1
expression [11-22]. The specific detection of TKTL1
protein in paraffin sections with JFC12T10 allowed
the discrimination between healthy TKTL1-negative
epithelium and TKTL1-positive carcinoma cells [7].
Mutations within the TKTL1 gene have been suggested to
tissue-specific transcripts of different sizes encoding
an enzymatically active transketolase protein as well
as different smaller protein isoforms [7]. Western blot
analyses of five human cancer cell lines demonstrated
that JFC12T10 identifies different TKTL1 protein isoforms
with molecular weights of 40 and 75 kDa, respectively [7],
the calculated molecular weight of the original TKTL1
protein being 65.4 kDa.
Using immunohistochemistry, TKTL1 was found over-
expressed in a variety of human cancer tissues, and a
strong TKTL1 signal correlated with tumor invasiveness
[23,24]. Langbein and coworkers described that 9 out of
10 tumors found to be metastatic also showed a strong
staining of TKTL1 using the JFC12T10 antibody [23]. In
contrast to TKTL1, TKT and TKTL2 expression was not
up-regulated in these tissues [23]. It was further proposed
that tumors characterized by an up-regulation of TKTL1
demonstrated a TKTL1-based pathway with increased
glucose metabolism and production of large amounts of
lactic acid [7]. The enhanced glucose metabolism of solid
malignant tumors with increased glucose consumption
and excess amounts of lactic acid production, even in the
presence of oxygen, is known as aerobic glycolysis, alsotermed “Warburg effect” [25,26]. The widespread clinical
application of the imaging technique positron-emission
tomography (PET) using the radiolabeled glucose analogue
FDG demonstrates such enhanced aerobic glycolysis in
most tumors [27]. Constitutive up-regulation of glucose
metabolism by tumor cells arises as an adaption to local
hypoxia [27] and TKTL1 should enable cells to catabolize
glucose in an oxygen-independent manner [7,8]. Indeed,
TKTL1 suppression in malignant cells resulted in
significantly slower cell growth as well as reduced
glucose consumption and lactic acid production [28].
TKTL1 overexpression in solid tumors was suggested to
correlate with enhanced aerobic glycolysis [29] and
resistance to chemotherapy and radiation [30]. However,
the postulated enzymatic key role of TKTL1 for the
energy metabolism of malignant cells has been a subject
of recent controversy [30-34]. A protein sequence
alignment of TKT and TKTL1 exhibited that TKTL1 lacks
several important amino acid residues necessary for the
enzymatic action of all TKT enzymes characterized so
far [31]. From the results of the spatial structure of
TKTL1 it was resumed that TKTL1 is unlikely to be
a thiamine-dependent protein capable of catalyzing
the TKT reaction [32]. Furthermore, two independent
research groups were unable to detect any transketo-
lase activity of a TKTL1 mimic protein. This was
generated from TKT via deletion of the 38 amino acid
residues from TKT, which are lacking in the original
TKTL1 sequence [33,34].
A positive staining of cancer tissues with the TKTL1-
specific antibody clone JFC12T10 was reported to correlate
with a poor patient outcome in some cancer entities
including laryngeal squamous cell carcinoma, non small
cell lung cancer, tumors of the ocular adnexa, papillary
thyroid carcinoma and rectal cancer, indicating TKTL1 as
a marker of prognostic relevance [15,19,23,24,35]. However,
other studies failed to show a correlation between staining
intensity for TKTL1 and clinical parameters [14,36-38].
Hence, the inconsistency of published results raised
concerns about the prognostic relevance of TKTL1. We
therefore decided to analyze the expression of TKTL1 in a
panel of 17 established malign cell lines and three benign
control cell types (two primary and one established
cell line) by immunohistochemistry, Western blot and
quantitative PCR (RT-qPCR). Further, we characterized
these cells by evaluating their survival after treatment with
the chemotherapeutic drugs taxane and cisplatin, and
ionizing radiation, respectively. In addition, glucose con-
sumption and production of lactic acid were measured in
all cell lines at 21% oxygen to address a potentially
increased “Warburg effect” that may correlate with suc-
cessful detection of TKTL1 expression by immunohisto-
chemistry, Western blot and RT-qPCR. In order to
compare results, immunohistochemistry and Western blot
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clones JFC12T10 and 1C10 as well as the polyclonal
anti-TKTL1 antibody Sigma Prestige.
Our results indicate that TKTL1 expression is rare in
cell lines tested and unrelated to both their rate of lactic
acid production and resistance against chemo- and
radiotherapy. Additionally, staining patterns of all three
TKTL1-specific antibodies were not matched. The
antibodies Sigma Prestige and 1C10 detected a single,
distinct protein band of TKTL1 at the expected molecular
weight in the TKTL1-transfected control cell line, and
were negative in all remaining cell lines tested. The
antibody clone JFC12T10 correctly detects the TKTL1
protein at the expected size of 65.4 kDa in these
transfected control cells and additional multiple protein
bands with different molecular weights, which were also
visible in all other tested cell lines.
Methods
Cell lines
The cell lines investigated herein were directly obtained
from the companies given in Table 1 to warrant their
correct identity. For all experiments described, each cell lineTable 1 Cell lines and primary cells
Name Tissue type
Fibroblasts Uterine fibroblasts
HTC116 Colorectal carcinoma
HEK 293- control Embryonic kidney cells
HEK 293-TKTL1 Embryonic kidney cells
HeLa Adenocarcinoma of the cervix
HepG2 Hepatocellular carcinoma
HT-29 Adenocarcinoma of the colon
HUVEC Human umbilical vein endothelial
JAR Choriocarcinoma
JEG Choriocarcinoma
23132/87 Adenocarcinoma of the stomach
MCF-7 Invasive breast ductal carcinoma
MDA-MB 231 Adenocarcinoma of the breast
Mel2a Metastatic melanoma
OVCAR Ovarian carcinoma
PA1 Teratocarcinoma of the ovary
SiHa Cervical carcinoma
SKOV3 Adenocarcinoma of the ovary
U251, U87 Glioblastoma
WiDr Adenocarcinoma of the colon
WS1 Embryo-derived skin fibroblasts
ATCC: American Type Culture Collection, Manassas, Virginia, USA (www.lgcstandards-atcc
DOD: Department of Dermatology, University of Würzburg Hospital, Germany; DOO
Ludwig-Maximilians-University, Munich, Germany; DSMZ: German Collection of
Germany (www.dsmz.de); IOP: Institute of Pathology, University of Würzburg, Gwas routinely cultured in a 1:1 mixture of DMEM/Ham's
F-12 supplemented with 10% (v/v) fetal calf serum (FCS)
and 10 ng/ml gentamycine (all reagents from PAA, Coelbe,
Germany) at 37°C in the presence of 5% CO2 and
21% oxygen. Cells were cultured in 75 ml culture
flasks (Biochrom, Berlin, Germany) as monolayers
and harvested at 80-90% confluence using a cell-
scraper (Biochrom) for further experiments. HEK293
cell transfectants stably producing full-length TKTL1
protein (293pCAG TKTL1) were used as positive
control cells. HEK293 cells transfected with empty
expression vector (293pCAG Δ) do not produce
TKTL1 protein and were used as negative control
cells. Both transfectants have been previously described
in detail [21]. For the present study the transfectants
were named as follows: 293pCAG TKTL1 =HEK293-
TKTL1 transfectants and 293pCAG Δ =HEK293-control
transfectants.
Immunohistochemistry of formalin-fixed,
paraffin-embedded cell pellets
Approximately 1x106 cells per cell line were harvested
upon trypsinization, washed twice with PBS and fixed forSource Literature
PC
DSMZ [60,61]
DOO [21]
DOO [21]
CLS [62]
CLS [63]
CLS [64]
cells PC
CLS [65]
CLS [66]
IOP [67,68]
CLS [69]
CLS [70]
DOD [71]
ATCC [72]
CLS [73]
ATCC [74]
CLS [64]
CLS [75]
CLS [76]
CLS [77]
.org); CLS: Cell Lines Services GmbH, Eppelheim, Germany (www.cell-lines-service.de);
: Department of Otorhinolaryngology, Head and Neck Surgery,
Microorganisms and Cell Cultures, Leibniz Institute, Braunschweig,
ermany.; PC: PromoCell GmbH, Heidelberg, Germany.
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centrifugation steps were performed at 280x g at 4°C for
10 min. The pellet was then re-suspended in 150 μl PBS
and mixed with the same quantity of pre-cooled 2%
high-melting agarose (Fermentas GmbH, St. Leon-Roth,
Germany). The mixture was cooled down on ice. The
resulting clot was first transferred to a sample-embedding
capsule and then to a 4% PBS-buffered formalin solution.
The dehydration with graded alcohols and xylene, and the
embedding into paraffin (Histosec, Merck, Darmstadt,
Germany) were done automatically in parallel to tissue
biopsy samples at the Institute of Pathology, University of
Würzburg, in a Leica ASP200 S embedding unit. The
resulting paraffinized cell clot samples were then set
into paraffin blocks. Paraffin blocks with cell samples
were cut into 2 μm thick sections and mounted up
on aminopropylethoxysilane (APES)-coated slides.
Slides for immunohistochemistry were rehydrated in
descending concentrations of ethanol before being
heated for antigen unmasking in 10 mmol/l sodium
citrate buffer (pH 6.0) in a microwave oven at 600 W
for 5 min. After rinsing in distilled water, inhibition
of endoperoxidase was performed by incubating sections
for 10 min in 3% H2O2 in methanol. Slides were washed
in PBS and incubated with 1% human immunoglobulin
(Beriglobin, CSL Behring, Marburg, Germany) in PBS for
15 min to block FC-receptors [39]. Subsequently, slides
were incubated with monoclonal mouse anti-TKTL1 anti-
body (clone JFC12T10, stock solution: 1 mg/ml; Linaris)
or polyclonal anti-TKTL-1 antibody (Sigma prestige
HPA000505, stock solution: 0.1 mg/ml; Sigma-Aldrich,
Deisenhofen, Germany) diluted in antibody dilutent
(DAKO, Hamburg, Germany). USB antibody used in
Western blotting was not applicable for immunohisto-
chemistry. Optimal antibody concentrations were deter-
mined in a series of dilutions with HEK293-TKTL1
transfectants and tumour tissue previously found to be
TKTL1 positive [37,40-43]. A dilution of 1:200 from the
stock solution was optimal for JFC12T10 and 1:20 for the
SigmaPrestige antibody. After 60 min of incubation at
room temperature in a humidified chamber, slides were
washed in PBS and incubated with the horseradish-
labelled LSAB2 secondary antibody mixture (DAKO)
according to the manufacturer’s protocol. Staining was
developed by adding 3,3’diaminobenzidine (DAB ready
to use, DAKO) with subsequent counterstaining using
haematoxylin. Afterwards, sections were dehydrated
by washing in graded ethanol and then embedded in
Vitro-Clud (Langenbrink, Germany). To obtain a maximum
of homogeneous results all staining procedures were carried
out in parallel in one session and repeated twice. Stained
cells were photographed at 40x magnification with a
KEYENCE Biozero Microscope (Keyence Corporation,
Osaka, Japan) applying Z-stack technology.Western blotting
For protein extraction, 1x106 cells each were lysed in
pre-cooled RIPA buffer (Pierce, Rockford, Ilinois)
containing phosphatase inhibitors (phosphatase inhibitor
cocktails set II, Calbiochem, Germany), proteinase inhibitors
(Complete, Roche, Germany) and 2,5 mmol/l Dithiothreitol
(DTT) reducing agent (Sigma-Aldrich). The mixture was
incubated for 30 min on ice, combined with a thorough
shaking every 10 min. Cell lysates were clarified of cell
debris by centrifugation at 14,000x g for 5 min through a
QIAshredder spin column assembly (Qiagen, Hamburg,
Germany) at 4°C. Protein concentration was determined
using the Bradford method [44] and coomassie brilliant blue
(Roti-Quant; Roth, Karlsruhe, Germany). Afterwards,
samples were mixed in 5x loading buffer (Fermentas),
denatured at 95°C for 5 min, chilled on ice and stored
at −20°C for further analysis. Equal amounts of proteins
(20 μg) were loaded on a 10% polyacrylamide gel
(SDS-PAGE) and electrophoresed. Proteins were then
blotted onto a nitrocellulose membrane (Schleicher &
Schuell, Dassel, Germany) for 45 min at 10 V using a
semi-dry transfer unit (PeqLab, Erlangen, Germany). The
protein transfer was confirmed by reversible membrane
staining with Ponceau solution (Sigma-Aldrich). To avoid
unspecific binding, the membrane was blocked with 5%
non-fat milk (Merck, Darmstadt, Germany) in phosphate
buffered saline (PBS)/Tween (0.05%) at room temperature
for 1 h. Subsequently, the membrane was incubated with
the respective primary anti-TKTL1 antibody at optimal
dilution (see below) in PBS/Tween containing 2% non-fat
milk at 4°C for 18 h. The following anti-TKTL1 antibodies
were used: mouse monoclonal antibody clone JFC12T10
(Linaris GmbH, Wertheim, Germany, stock solution:
1 mg/ml, dilution 1:2,500), polyclonal rabbit Sigma Prestige
antibody (HPA000505, Sigma-Aldrich, stock solution:
0.1 mg/ml, dilution 1:1,000), and mouse monoclonal
antibody clone 1C10 (US Biological, Biomol GmbH,
Hamburg, Germany, stock solution: 1 mg/ml, dilution
1:2,500). After washing with PBS, membranes were incu-
bated with horseradish peroxidase-conjugated secondary
antibodies goat-anti-mouse or goat-anti-rabbit, respectively
(KPL Gaithersburg, USA, both diluted 1:10,000, stock
solution: 0.5 mg/ml) for 60 min at room temperature.
A monoclonal mouse anti-β-actin primary antibody,
diluted 1:10,000, (Abcam, Cambridge, USA) was used
as loading control. Immunoblots were visualized by
home-made enhanced chemiluminescence (ECL) consisting
of a mixture of 10 ml of solution A (50 mg Luminol
(Sigma-Aldrich A4685) dissolved in 200 ml 0,1 mol/l
Tris–HCl (pH 8,6)), 1 ml Solution B (11 mg para-
hydroxycoumarinacid (Sigma-Aldrich, C9008) dissolved in
10 ml DMSO) and 3 μl of 30% H2O2 [45] with subse-
quent exposure on an X-ray film (Fuji Super RX medical
X-ray films; Fuji Photo Film, Düsseldorf, Germany) for
Kämmerer et al. BMC Cancer 2015, 15:2 Page 5 of 16
http://www.biomedcentral.com/1471-2407/15/230 sec (shown in Figure 1) or for 3 min (USB) and 5 min
(SigmaPrestige), respectively (shown in Additional file 1:
Figure S1).
RNA extraction and cDNA synthesis
1x106 cells each were disintegrated in Trizol reagent
(Invitrogen Life Technologies; Darmstadt, Germany).
Total RNA was extracted from Trizol as recommended
by the manufacturer. RNA integrity was verified using
the Experion automated electrophoresis station (Bio-Rad
Laboratories Inc.; Munich, Germany) and the RNA
concentration was measured at 260 nm. For first
strand cDNA synthesis, 1 μg total RNA was employed
using the iScriptcDNA synthesis kit from BioRad. The
cDNA synthesis of 1:2 diluted cDNA was performed
by heating at 25°C for 5 min, at 42°C for 30 min, and
at 85°C for 5 min.
Reverse Transcriptase (RT) quantitative polymerase chain
reaction (qPCR)
Quantitative PCR (qPCR) was performed with MESA
Green qPCRMasterMix Kit for SYBR Green containing
Meteor Taq hotstart polymerase (Eurogentic GmbH, Köln,
Germany). Three sets of TKTL1 primer pairs were used:
primer pair 1 (150 bp), forward: TAACACCATGACGCC
TACTGC, reverse: CATCCTAACAAGCTTTCGCTG [7]ImmunohistochemistryLiving cell Western Blot
Part-1
culture
C 12 10 S k
tin
TKTL1
JF T igma prest. M J P
s 70
UAk
la
st 55
br
o
b 40
35
Fi
25
6
70
55
T 
11
40
H
C 35
25
70
-
55
29
3
tro
l
40
35E
K 
co
n
25
H
70
5593
-
1
40K 
2
KT
L
35H
E T
25
70
La
55
H
e 40
35
25
2
70
55
p 
G
40
H
e
35
25
70
55
29
40
35H
T-
25
EC
70
55
H
UV 40
35
25
Part -2
ImmunohistoLiving cell
culture
JFC 12T10
R
JA
EGJ
/8
7
13
2
23
7
C F
-
M
1
B 
23
A-
M
M
D
e
l 2
a
M
e
AR
O
VC
A
O
Figure 1 Detection of TKTL1 expression on protein levels. The cell mo
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ACC [28]; primer pair 3 (151 bp), forward: GGTAT
CTGTTGGTGACGATGGT, reverse: GCACATCCCCTT
GGCATTGG [35]. TKTL1 primer pair 1 is located in the
non-coding region, and primer pairs 2 and 3 are located in
the coding region of TKTL1. The following primer pairs
were used as reference genes: peptidyl propyl isomerase
A (PPIA; access. No. NM_021130.3), forward: TGTCC
ATGGCAAATGCTGGACCC, reverse: GCGCTCCAT GG
CCTCCAC AA (140 bp); β-actin (access. No. NM_001101),
forward: CCTTGCCATC CTAAAAGCC, reverse: CACG
AAAGCAATGCTATCAC (96 bp). qPCR reactions were
performed on a CFX96 real-time PCR system (Bio-Rad)
operated by CFX Manager Software (version 3.0). The cycler
protocol was 5 min at 95°C, 40 cycles of 15 sec at
95°C, 60 sec at 60°C, and 5 min at 72°C. Gene of
interest expression was normalized to the reference
genes PPIA and β-actin [46]. Fold expression was calcu-
lated with the ΔΔCq method [47]. Post-amplification
melting curves were controlled to exclude primer-dimer
artifacts and contaminations. Tktl1 mRNA expression was
rated positive if the cycle number of the amplification
reaction was obviously below the cycle number for
HEK293-control transfectants with the three primer
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Western blot [21].Glucose consumption and lactate production
Cells were seeded at 1x105 cells/ml in 48-well flat
bottom tissue plates (TPP; Biochrom) with culture
medium and were grown for 24 h. Afterwards, medium
was completely replaced, and glucose consumption and
lactate production at 21% oxygen were analyzed 24 h
later. Cell-free supernatant was snap frozen for analysis
and cell numbers were calculated with the crystal violet
assay [48]. Frozen supernatants were sent to the central
laboratory of the University Hospital of Würzburg,
thawed and immediately analyzed for glucose and
lactate with the Cobas 8000 modular analyzer series
(Roche Diagnostics; Mannheim, Germany). Glucose
consumption was calculated as the difference between
glucose concentration in cell-free control medium
(16.4 ± 0.2 mol/l) (mean ± standard deviation) and glu-
cose concentration remaining in the supernatant of
cell cultures after an incubation time of 24 h. Lactate
production was calculated as the difference between
lactate concentration in the supernatant of cell cul-
tures after an incubation time of 24 h and lactate
concentration determined in cell-free control medium
(0.29 ± 0.04 mol/l) (mean ± standard deviation). Both
results were then correlated to the cell number and
displayed as consumption/production per 10,000 cells.Paclitaxel and cisplatin sensitivity assay
Adherently growing cell lines were seeded at 5,000
cells per 100 μl of cell culture medium in a 96 well
flat bottom tissue culture plate (NUNC Inc., VWR
International, Ismaning, Germany) and grown for 24 h
prior to treatment with chemotherapeutic drugs. Then,
100 μl cell culture medium containing paclitaxel or
cisplatin (both from Sigma-Aldrich) were added, resulting
in final drug concentrations ranging from 1% to 200% of
the reported peak plasma concentrations achievable in
patients [49]. The maximum plasma concentration was
given as 15.9 nmol/ml (13.6 μg/ml) for paclitaxel and
12.7 nmol/ml (3.8 μg/ml) for cisplatin [50]. Cells were
incubated for further 24 h and cell viability was measured
with Cell Counting Kit-8 (CCK-8; Sigma-Aldrich). In brief,
supernatant was carefully removed from the cells and a
mixture of 100 μl fresh cell culture medium and 10 μl
CCK-8 solution were added per well. Cells were incubated
for 1 h at 37°C in a humidified incubator before analyzing
the substrate reaction at 450 nm in a plate reader (Tecan
GENios plus, Tecan Deutschland GmbH, Crailsheim,
Germany). All analyses were performed in triplicates.
Results were analyzed with the GraphPad Prism software
calculating dose–response curves and IC50 values.Radiosensitivity
Cell lines were seeded at 100 cells in 200 μl cell cul-
ture medium in a 96 well flat bottom tissue culture
plate (TPP; Biochrom) 24 h prior to radiation. Graded
X-irradiation (2, 4, 6 and 8 Gy) was then performed
at room temperature using a 6 MV linear accelerator
(Primus, Siemens Concord, CA, USA) at a dose rate
of 3 Gy/min. Control cells were treated in a similar
way, but without irradiation. Each radiation dose was
applied in triplicates. 20 min after irradiation cells
were cultivated at 37°C in a humidified incubator at 5%
CO2. Medium was completely replaced after 60 min to start
with fresh growth conditions. In addition, cell medium was
replaced on day 4 and day 8. Ten days after irradiation, the
CCK-8 assay was performed as described above.
Results
Detection of TKTL1 protein expression by
immunohistochemistry
So far, TKTL1 protein expression was described primarily
in paraffin-embedded tumor tissue. Hence, in order to
produce comparable datasets, paraffin-embedded cell
pellets of all selected cell lines (n = 20) served to analyze the
expression of TKTL1 protein by immunohistochemistry.
The cell lines assessed in the present study are summarized
in Table 1, including tissue origin, supplier and references.
In addition, TKTL1-negative human embryonic kidney cells
HEK293 have been stably transfected with the expression
plasmid pCAG or with a pCAG-based TKTL1 expression
plasmid, which resulted in strong expression of the protein,
as described elsewhere [21]. All cell lines have been
analyzed by immunohistochemistry with the mouse mono-
clonal antibody clone JFC12T10 and with TKLT1-specific
Sigma Prestige (rabbit polyclonal).
Immunohistochemical staining with JFC12T10 and Sigma
Prestige antibodies showed a strong cytoplasmatic staining
in HEK293-TKTL1 transfectants, with an additional nuclear
staining by the Sigma Prestige polyclonal antibody.
JFC12T10, but not the Sigma Prestige antibody also stained
the cytoplasm of TKTL1-negative HEK293-control cells.
The staining intensity of JFC12T10 in HEK293-control and
HEK293-TKTL1 transfectants was comparable indicat-
ing an unspecific staining pattern of JFC12T10 in
HEK293-control transfectants (Figure 1 and Table 2).
Cytoplasmic staining of the 17 malign and the three
benign cell lines with JFC12T10 ranged from weak
(“+”) to very strong (“+++”) (Figure 1, Table 2). Only
HT-29 cells remained unstained by JFC12T10. In con-
trast, cytoplasmic staining intensity with Sigma Prestige
polyclonal antibody was faint (“[+]”) in eight cell lines
(only PA1 cells were stained “+”), while no staining was
observed in the cytoplasm of the remaining eight cell lines
(Figure 1, Table 2). With this antibody, no or only weak
background staining was observed in benign cells. Both
Table 2 Immunohistochemical data
Cell line Monoclonal anti-TKTL1 antibody JFC12T10 Polyclonal anti-TKTL1 antibody Sigma Prestige
Nucleus Cytoplasm Cell surface Nucleus Cytoplasm Cell surface
control:
HEK 293-control - ++ - - - -
HEK 293-TKTL1 - +++ - + +++ -
benign:
Fibroblasts - ++ - - [+] -
HUVEC - + ++ - [+] -
WS1 - + ++ - - -
malign:
HCT116 - ++ - - [+] -
HeLa - +++ - - - -
HepG2 [+] ++ - + - -
HT-29 - - - - - -
JAR - ++ - - [+] -
JEG - ++ - - [+] -
23132/87 - + - - - -
MCF-7 [+] - - - [+] -
MDA-MB 231 - ++ - - - -
Mel2A - ++ - - [+] -
OVCAR + ++ - - - -
PA1 - + - - + ++
SiHa - ++ - - [+] +
SKOV3 - ++ - - [+] -
U251 - + - - - -
U87 + +++ - - [+] -
WiDr - +++ - - - -
The semiquantitative staining pattern is given for both antibodies (JFC12T10 and Sigma prestige) based on the analysis of two independent staining results per
cell line per antibody. Legend: “-“: negative; “[+]”: faint positive; “+”: positive; “++”: strong positive; “+++” very strong positive.
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http://www.biomedcentral.com/1471-2407/15/2antibodies stained the nuclei of HepG2 cells, and JFC12T10
additionally stained the nuclei of MCF-7, OVCAR, and
U87 cells. While the Sigma Prestige polyclonal antibody
stained the surface of PA1 and SiHa cells, a surface staining
with JFC12T10 was seen in HUVEC and WS1. The most
obvious mismatch of staining results from JFC12T10 and
the Sigma Prestige antibody was found for HeLa, 23132/87,
OVCAR, U251, WiDr and WS1 cells. These six cell
lines demonstrated a strong staining by JFC12T10,
but no or faint staining by Sigma Prestige antibody
(Figure 1, Table 2).
Detection of TKTL1 protein expression by Western blot
analysis
TKTL1 expression was assessed in whole cell lysates of
all 20 cell lines and the two control HEK293 cells by
Western blot with the monoclonal anti-TKTL1 antibody
clones JFC12T10 and 1C10 as well as with the polyclonal
Sigma Prestige. All three antibodies detected TKTL1protein in HEK293-TKTL1 transfectants (Figure 1) with
an apparent molecular weight of 65 kDa, which is the
expected molecular weight of TKTL1 protein. In contrast
to Sigma Prestige and 1C10, JFC12T10 detected additional
proteins with molecular weights ranging from 27 kDa to
70 kDa in HEK293-TKTL1 transfectants (Figure 1,
Table 3). These additional proteins were also deteced
in TKTL1-negative HEK293-control cells and have
previously been reported to be insensitive towards transi-
ent reduction of TKTL1 expression using specific siRNA
oligonucleotides [21]. The most prominent protein had a
molecular weight of 27 kDa and was detected in all
cell lines, except for WS1 fibroblast cells and primary
fibroblasts. Protein bands with an apparent molecular
weight of 37, 40, 45, and 55, 70, 100, and >120 kDa were
observed in lysates of the majority of cell lines stained with
JFC12T10. These protein bands are interpreted as back-
ground signals due to the very weak staining even after
long exposure (see Additional file 1: Figure S1). Strikingly,
Table 3 Western blot data obtained with the three anti-TKTL1 antibodies JFC12T10 (monoclonal), 1C10 (monoclonal)
and Sigma Prestige (polyclonal)
Cell line Antibody
JFC12T10 1C10 Sigma Prestige
Most prominent
signal (kDa)
2nd prominent
signal (kDa)
Further signals (kDa) Most prominent
signal (kDa)
Further signals (kDa)* Most prominent
signal (kDa)
Fibroblasts - - 27/40/55/60 - - -
HCT116 27 - multiple - 37/55/65 -
HEK 293 -control 27 37 45/55/65/70 - - -
HEK 293-TKTL1 65 27/37 multiple 65 - 65
HeLa 27 - multiple - 37/40/47/65 -
HepG2 27 37/45 multiple - - -
HT-29 27 - - - - -
HUVEC 27 37/40/45/50 multiple - - -
JAR 27 37 multiple - 37/55 -
JEG 27 40 multiple - - -
23132/87 27 37/45 multiple - - -
MCF-7 27 - multiple - 37/40/50/70 -
MDA-MB 231 27 40 multiple - 37/40 -
Mel2A 27 45/40 multiple - 45/55/70 -
OVCAR 27 42 multiple - 37/40/50/90 -
PA1 27 37 multiple - 55 -
SiHa 27 42 multiple - - -
SKOV3 27 37 multiple - 37740/55 -
U251 27 40/45/55 multiple - 45 -
U87 27 55 multiple - 45 -
WiDr 27 42 multiple - - -
WS1 - - 40/55/70* 40/55/65 -
Western blot staining results with the antibodies JFC12T10, 1C10 and Sigma Prestige of at least two independent blots per cell line per antibody. Legend:
“-“ no staining (no signal); “*” very faint staining. The polyclonal Sigma Prestige antibody did not show any signals despite the positive control.
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http://www.biomedcentral.com/1471-2407/15/2Sigma Prestige and 1C10 antibodies did not detect any
TKTL1 protein in 15 of 17 malign cell line studied.
Monoclonal antibody clone 1C10, which was generated
against full-length TKTL1 protein, produced very faint
signals with higher and lower molecular weights than
expected for TKTL1 in some of the cell lines tested
(Figure 1, Table 3). The signal intensity was not increased
by an extended exposure time of 3 min. After this very
long exposure time, 1C10 detected a very faint signal at
the expected molecular weight of TKTL1 in JAR cells.
The polyclonal Sigma Prestige antibody, raised against
the N-terminus of TKTL1, did not produce any sig-
nals except in the positive control HEK293-TKTL1
cells, even after an extended exposure time of 5 min
(Additional file 1: Figure S1). To summarize, all three
TKTL1-specific antibodies recognize exogenously expressed
recombinant TKTL1 protein in HEK293-TKTL1 transfec-
tants. Monoclonal antibody 1C10 did not show any specific
signals in the three benign and in 15 out of 17 malign celllines tested. Polyclonal Sigma Prestige antibody failed
to detect TKTL1 in all cell lines tested, indicating a
lack of endogenous TKTL1 protein. In contrast, monoclonal
antibody JFC12T10 detected numerous additional protein
bands with apparent molecular weights above or below the
calculated size of TKTL1 (Figure 1 and Table 3). From our
data, we cannot exclude the possibility, that the multiple
protein signals detected by JFC12T10 antibody, in addition
to the full length signal, represent putative smaller TKTL1
fragments derived from the C-terminus, which were
not detected by Sigma Prestige and 1C10 antibodies raised
against the N-terminus (Sigma Prestige) or the full-length
protein (1C10) respectively.
Detection of tktl1 mRNA expression by quantitative
RT-PCR (RT-qPCR)
Quantitative RT-PCR (RT-qPCR) was performed with
three different primer pairs specific for the three tktl1
mRNA splice variants available in GenBank (PubMed)
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for all cell lines investigated are shown in Table 4, while
Table 5 summarizes basic quantitative PCR data for all
three primer pairs. For this, HEK293-TKTL1 transfec-
tants, HEK293 control transfectants and JAR and U251
cells were analyzed. JAR and U251 were identified to
weakly express endogenous tktl1 mRNA with all three
primer pairs (Table 4). Primer pair 1 (located in the
non-coding region of TKTL1 gene) did not recognize
coding TKTL1 mRNA in HEK293-TKTL1 transfectants,
whereas primer pairs 2 and 3 did. In comparison to
JAR and U251 cells, the abundance of tktl1 mRNA
in the other malign and benign cells was comparable
to or below levels of the TKTL1-negative HEK293 con-
trol cell lines, and thus defined as negative (Table 4).
The relative expression levels of tktl1 in JAR and U251
were increased up to 560-fold in comparison to the
other cells (example for primer pair 3 and JAR and
MDA-MB 231).Table 4 Relative normalized quantification of TKTL1 gene exp
TKTL1(2) and TKTL1(3)
Cells TKTL1(1) TKTL1(2
Mean ± SD Cq Mean ±
HTC116 0.071 ± 0.063 31.79 7.4x10−4
HEK 293-TKTL1 0.014 ± 3.1x10−4 34.66 48.9 ± 1
HEK 293-control 0.117 ± 0.0046 **) 31.63 28.4x10−
HeLa 0.379 ± 0.041 28.40 5.0x10−5
HepG2 1.3x10−3 ± 9.2x10−4 36.75 2.0x10−5
HT-29 2.5x10−3 ± 1.6x10−3 35.36 2.0x10−5
HUVEC 0.194 ± 0.05 32.23 2.4x10−4
JAR 0.462 ± 0.09 25.64 0.037 ±
JEG 0.039 ± 0.006 30.12 1.6x10−4
23132/87 9.9x10−3 ± 0.014 34.13 9.0x10−5
MCF-7 2.4x10−4 ± 0.002 34.76 1.0x10−5
MDA-MB 231 3.5x10−4 ± 3.3x10−4 37.34 1.0x10−5
Mel2a 0.161 ± 0.012 30.81 1.6x10−3
OVCAR 0.333 ± 0.073 28.71 5.0x10−5
PA1 0.021 ± 0.007 33.36 5.1x10−4
SiHa 0.023 ± 0.020 32.33 1.0x10−5
SKOV3 0.084 ± 0.062 31.16 5.1x10−4
U251 1.000 ± 0.117 22.84 0.046 ±
U87 1.4x10−3 ± 2.8x10−4 36.81 1.0x10−5
WiDr 3.6x10−3 ± 2.9x10−4 34.95 2.0x10−5
WS1 0.010 ± 0.007 35.56 1.0x10−5
For the quantification of TKTL1 gene expression, actin and PPIA were used as endo
cycle of quantification (Cq) for each PCR amplicon is indicated (Cq presents the cyc
threshold level). Cq values higher than the cut-off of 35 was not considered as a re
TKTL1 in most tested malign and benign cell lines are decreased in comparison to
with primer pairs 2 and 3 were successfully proofed for TKTL1 sequence, whereas f
pairs were without TKTL1 sequence (data not shown).Glucose consumption and lactic acid formation
High expression of TKTL1 was put into context of en-
hanced glucose consumption within the pentose-
phosphate pathway, resulting in increased lactic acid pro-
duction [7]. In order to correlate both parameters with
TKTL1 expression, glucose usage and lactic acid produc-
tion were analyzed for confluent cell cultures after 24 h of
culture at 21% oxygen. Data are summarized in Additional
file 2: Table S1. Mean glucose consumption was
7.4 mmol/l per 10,000 cells (range: 1.9-21.4 mmol/l) after
24 h across all cell lines tested (n = 20) (Figure 2, light grey
columns). The corresponding lactic acid production had a
mean value of 1.03 mmol/l per 10,000 cells (range: 0.2-
4.1 mmol/l) after 24 h (Figure 2, dark grey columns).
All cell lines including benign cells showed lactic
acid production 21% oxygen, thus demonstrating the
“Warburg effect”. Glucose consumption and lactate pro-
duction were correlated as expected. HCT116, HT-29,
23132/87, SiHa, and SKOV3 cells displayed the highestression with the three published primer pairs TKTL1(1),
) TKTL1(3)
Stabw Cq Mean ± Stabw Cq
± 8.0x10−5 30.46 3.4x10−3 ± 9.4x10−4 28.86
.14 17.68 48.9 ± 0.80 17.26
4 ± 2.5x10−4 **) 28.70 0.010 ± 0.001 **) 27.83
± 2.0x10−5 33.13 0.012 ± 0.004 26.04
± 3.0x10−5 35.03 1.1x10−4 ± 2.0x10−5 33.02
± 2.0x10−5 33.83 4.0x10−5 ± 3.0x10−5 33.84
± 2.3x10−4 33.72 1.8x10−4 ± 3.0x10−5 34.99
0.0031 25.15 0.028 ± 8.30x10−4 24.08
± 4.0x10−5 30.90 3.6x10−4 ± 3.0x10−5 29.58
± 9.0x10−5 32.81 1.6x10−4 ± 1.0x10−5 32.79
± 1.0x10−5 36.85 1.0x10−5 ± 1.0x10−5 35.64
± 1.0x10−5 33.87 5.0x10−5 ± 1.0x10−5 32.79
± 3.4x10−4 28.52 4.4x10−3 ± 2.3x10−4 28.69
± 6.0x10−5 33.51 1.7x10−4 ± 5.0x10−5 32.33
± 1.0x10−4 30.83 1.3x10−3 ± 1.4x10−4 30.06
± 1.0x10−5 35.57 4.0x10−5 ± 4.0x10−5 34.18
± 1.4x10−4 30.43 1.2x10−3 ± 3.6x10−4 29.99
0.0015 23.16 0.036 ± 9.7x10−4 22.06
± 1.0x10−5 35.97 7.0x10−5 ± 1.0x10−4 33.84
± 3.0x10−5 34.14 8.0x10−5 ± 2.0x10−4 33.13
± 1.0x10−5 38.50 6.0x10−5 ± 4.0x10−5 35.59
genous controls. In addition to values of relative normalized expression the
le number at which the amount of amplified PCR amplicon reaches the
liable Cq expression value. It is obvious, that the relative expression levels of
JAR and U251. For HEK293-TKTL1 transfectants, the PCR amplicons amplified
or HEK293-control transfectants, amplicons amplified with the three primer
Table 5 Comparison of PCR efficiency for the TKTL1 gene obtained with the three primer pairs
Cell line Primer pairs E (%) Slope R2 Cq (1:5) Cq (1:320) Cq (NTC)
HEK293-TKTL1 TKTL1(1) —— ——— —— 35.38 ± 0.78 35.95 ± 0.58 >40
TKTL1(2) 95.7 −3.429 0.991 22.09 ± 0.04 28.29 ± 0.46 >38
TKTL1(3) 94.9 −3.451 0.997 22.05 ± 0.24 28.14 ± 0.20 >40
PPIA 94.2 −3.470 0.994 22.78 ± 0.25 29.15 ± 0.10 >38
β-actin 95.1 −3.445 0.999 19.63 ± 0.03 25.89 ± 0.02 >32
HEK293-control TKTL1(1) ——— ——— ——— 33.74 ± 1.19 35.89 ± 0.85 >37
TKTL1(2) ——— ——— ——— 27.78 ± 0.03 27.98 ± 0.02 >37
TKTL1(3) ——— ——— ——— 30.33 ± 0.51 33.87 ± 1.01 >35
PPIA 90.2 −3.581 0.999 17.39 ± 0.05 23.94 ± 0.08 >35
β-actin 91.1 −3.554 1.000 17.38 ± 0.08 23.79 ± 0.06 >31
U251 TKTL1(1) 100.3 −3.315 0.987 26.44 ± 0.32 32.49 ± 0.10 >39
TKTL1(2) 103.5 −3.242 0.997 27.78 ± 0.02 33.69 ± 0.42 >36
TKTL1(3) 103.3 −3.246 0.989 26.69 ± 0.10 32.88 ± 0.04 >36
PPIA 99.3 −3.339 0.996 18.92 ± 0.07 25.08 ± 0.07 >37
β-actin 99.3 −3.339 1.000 15.53 ± 0.02 21.57 ± 0.02 >31
JAR TKTL1(1) 94.3 −3.467 0.987 27.67 ± 0.567 33.93 ± 0.421 >40
TKTL1(2) 92.1 −3528 0.974 28.64 ± 0.26 35.42 ± 0.53 >36
TKTL1(3) 90.1 −3.584 0.938 27.91 ± 064 34.48 ± 0.56 >37
PPIA 93.5 −3.489 0.995 14.82 ± 0.01 24.99 ± 0.05 >40
β-actin 98.1 −3.367 0.999 14.82 ± 0.01 20.96 ± 0.02 >31
The results are shown for the HEK293-TKTL1 and HEK293-control transfectants as well as for the cell lines JAR and U251 with the highest expression levels. The
following information about the performance of RT-qPCR for the three TKTL1 primer pairs as well as for the primer pairs for reference (housekeeping) genes
β-actin and PPIA is given: the PCR efficiency (E in %) and the slope of the standard curves (a PCR efficiency of 100% corresponds to a slope of −3.32 and a
slope of less −3.32 is indicative of a PCR efficiency <100%), the correlation coefficient R2 reflecting the linearity of the standard curve (ideally, R2 = 0.999) and the
quantification (threshold) cycles Cq for cDNA dilutions 1:5 and 1:320. In addition, Cq values for no template controls (NTC) are shown. The amplification efficiencies
of TKTL1 gene and the endogenous references genes β-actin and PPIA are comparable. It is worth to mention that the performance of PCR with the three primer
pairs did not demonstrate a dynamic range for the enzyme reaction allowing to construct a standard curve (copy number versus Cq value), and therefore to calculate
the efficiency of the enzyme reaction.
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http://www.biomedcentral.com/1471-2407/15/2levels of glucose consumption and lactate production,
whereas fibroblasts, HepG2, HUVEC, JEG, JAR, Mel2a,
U251, and U87 displayed the lowest levels (Figure 2).
JAR and U251 revealed to be the only cell lines within
the panel analyzed in the present study to express
TKTL1. Both cell lines did not demonstrate an outstand-
ing glucose consumption and production of lactic acid.
Effects of paclitaxel, cisplatin and radiation on cell
viability
Paclitaxel and cisplatin are widely used chemotherapeu-
tic drugs for clinical treatment of solid cancers and are
suitable for sensitivity tests. Therefore, all selected cell
lines (n = 20) were subjected to treatment with pacli-
taxel and cisplatin in concentrations ranging from
0.2-31.8 nmol/ml and 0.1-25.4 nmol/ml, respectively.
Representative results of dose–response curves after
treatment with paclitaxel and cisplatin are shown
(Figure 3A, 3B). From the resulting survival curves,
IC50 values were calculated (Figure 3C, 3D). HUVEC,
HeLa and PA-1 cells were highly sensitive to paclitaxel and
cisplatin (IC50 < 5 nmol/ml), whereas U251 and MCF-7were resistant to paclitaxel and Mel2A, and 23132/87 and
HepG2 were resistant to cisplatin (IC50 > 35 nmol/ml). JAR
cells displayed intermediate and high sensitivity towards
placlitaxel and cisplatin, respectively (Figure 3). Thus, the
investigated cell lines exhibited a broad range of resistance
and sensitivity to paclitaxel and cisplatin.
Next, all selected cell lines were irradiated at doses
ranging from 2 to 8 Gy and survival was determined.
Representative dose–response curves for radiation are
shown for JAR, U251, WiDr, OVCAR, PA1, HeLa,
MCF7, and JEG cell lines in Figure 4A. Radiosensitivity
was derived from the surviving fraction of cells at
2 Gy. This dose was effective at killing the majority
of irradiated HUVEC (surviving fraction 2 ± 1%), and
larger doses led to complete eradication of HUVEC
(data not shown). All cell lines tested (n = 20) demon-
strated a broad range of radiosensitivity. The stomach
cancer cell line 23132/87 was highly resistant to radiation
and grew to a surviving fraction of 163 ± 1.8% (Figure 4B).
WS1, WiDr, HeLa, HCT116, HT29, and PA1 cells
displayed strong resistance to radiation, with a survival
fraction at 2 Gy of approximately 100% (Figure 4B). In
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http://www.biomedcentral.com/1471-2407/15/2contrast, HepG2, JAR, fibroblasts and HUVEC cells were
characterized by radiosensitivity, with survival fractions
below 50%. U251 cells revealed intermediate sensitiv-
ity towards radiation, with a survival percentage (2Gy)
of 64 ± 16%. In summary, the tested cell lines demon-
strated broadly varying degrees of radiosensitivity.
TKTL1 expression and relation to chemo- and radioresistance
as well as to the “Warburg effect” in vitro
Performing RT-qPCR with three different primer pairs,
we identified two of 17 malign human cell lines (12%)
characterized by weak endogenous tktl1 mRNA expression
(JAR and U251). Immunohistochemical proof of TKTL1
protein in cytoplasm, the expected location of TKTL1 as a
protein which is supposed to be instrumental in the
pentose-phosphate pathway, was successful in these two
cell lines with JFC12T10. A very faint staining was seen for
JAR cells while U251 cells were negative using Sigma
Prestige polyclonal antibody, thus confirming negativeWestern blot results. All other cell lines demonstrated
much lower tktl1 mRNA expression levels and no detec-
tion of TKTL1 protein in cell lysates by anti-TKTL1 anti-
bodies 1C10 and Sigma Prestige, but multiple detections
of proteins with apparent molecular weights above or
below the calculated size of TKTL1 by anti-TKTL1 anti-
body JFC12T10. A relation of glucose consumption, lactic
acid production and chemo- and radioresistance with ex-
pression levels of TKTL1 was not observed in any cell line
tested in the present study. JAR and U251 cells did not
show outstanding “aggressiveness” as measured by their
resistance to both chemotherapeutic drugs and radiation
or their ability to produce lactate (Figures 2, 3 and 4).
While U251 was resistant to paclitaxel treatment and
moderately sensitive to cisplatin, JAR cells were sensitive
to both chemotherapeutic drugs (Figure 3). In comparison
to most other cells tested, both cell lines were sensitive to
radiation (Figure 4) and showed a moderate Warburg
effect (Figure 2). Therefore, the proposed link between
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http://www.biomedcentral.com/1471-2407/15/2TKTL1 expression and chemo- and/or radioresistance as
well as increased lactic acid formation by tumor cell
lines was not confirmed by our results. In fact, TKTL1
expression was generally rare among the cell lines tested
herein.
Discussion
Transketolase-like 1 (TKTL1) has gained increased
attention due to several studies showing a TKTL1-positive
staining of malignant tumor tissue of different origins
[15,16,20,22-24,35,40,41,43,51] and its subsequent designa-
tion as a “proto-oncogene” [9]. Furthermore, several cancer
cell lines have been reported to be positive for TKTL1
protein upon Western blot analysis [7,21,29,52-54],
cyto-immunohistochemistry [50,55] and RT-qPCR. For
example, Sun and coworkers analyzed TKTL1 expression
in six HNSCC cell lines via Western blot with the
JFC12T10 antibody and found that TKTL1 was relatively
overexpressed in two cell lines (FaDU and UM22B)
compared with levels in normal mucosal samples [29].
In this study, we tested three commercially available
anti-TKTL1 antibodies for Western blot and immuno-
histochemistry staining as well as three primer pairs
used in previously published work for the detection of tktl1
mRNA by RT-qPCR [7,28,35]. Two independent antibody
batches of each antibody were tested with identical results
in Western blot and immunohistochemistry experiments.
The reliability and specificity of each antibody and
primer pair was addressed and thoroughly quantified
using HEK293-TKTL1 transfectants producing full-length
TKTL1 and their TKTL1-negative counterparts HEK293-
control cells [21]. Assessment of tktl1 mRNA expression
disclosed a strong expression of the transgene in HEK293-
TKTL1 cells. Amongst all other cancer cell lines tested,
only JAR and U251 cells exhibited an – albeit very weak -
expression, with the remaining cell lines expressing levels
of tktl1 transcripts comparable or even lower than the
TKTL1-negative HEK293 controls. The discrepant results
for RT-qPCR and protein expression described by us for
several cell lines used in this study were also observed by
Benz et al. for cell lines tested by them (Figure 1a + b in
[52]). For example, they found a TKTL1 signal in SW620
cells with Western blot using the JFC12T10 antibody, but
no signal with RT-qPCR. Vice versa, SW948 cells are
positive for tktl1 mRNA but negative for TKTL1 protein
[52]. In contrast, Kayser at al. discuss a tight correlation of
immunohistochemically detected TKTL1 expression using
JFC12T10 and mRNA despite “doubts of the specificity of
the antibody clone JFC12T10” [20] but they do not
present results for this statement.
HeLa cells [56], colorectal carcinoma cell line HCT-116
[28] and other carcinoma cell lines [41,52] have been
reported to express tktl1 mRNA. In contradiction,
Hartmannsberger et al. noted the absence of endogenoustktl1 mRNA in a panel of different tumor cells including
HeLa and MCF-7 [21], which is consistent with our
results and was further corroborated by results from
Mayer et al. [54]. However, by using a primer pair identical
to our primer pair 1 located in the non-coding region in a
standard 40 cycles RT-PCR, Chen et al. found tktl1 mRNA
in HeLa cells [56]. Bentz and coworkers identified WiDr
cells as negative for tktl1 mRNA [52] in accordance with
our results. However, in contrast to our study, they
observed high expression of tktl1 mRNA in HT-29 cells
[52]. Discrepancies between our and other RT-qPCR
and PCR data could be due to either different expres-
sion profiles of the cell lines in different laboratories,
(un)authenticated cell lines or varying subclones [57,58].
In summary, our results suggest that tktl1 mRNA expres-
sion is a rare phenomenon in a broad panel of malign and
benign cell lines in vitro.
Interestingly, the vast majority of studies based on
antibody-based techniques published so far used the com-
mercially available mouse monoclonal IgG2b anti-TKTL1
antibody clone JFC12T10, first described in 2005 [7].
JFC12T10 was generated against a 22 kDA C-terminal
fragment of a recombinant TKTL1 protein. JFC12T10
stained a histidine-tagged full length TKTL1 protein
expressed in E. coli with putative smaller cleavage
products. Furthermore, JFC12T10 showed a unique
expression pattern of five different tumor cell lines
with a predominant protein band at 75 kDa by Western
blot analysis [7]. Indeed, the cell lines investigated in the
present study showed a faintly stained protein band at
approximately 75 kDa, among numerous other protein
bands. However, for most of the cells, JFC12T10 detected
approximately 10 different proteins with a predominant
band at approximately 27 kDa. This staining pattern
was comparable to results obtained by using JFC12T10 in
HEK293-control transfectants, which are devoid of
TKTL1 protein [21]. This indicates multiple unspecific
binding targets recognized by JFC12T10 in a broad variety
of cell lines, including the HEK293-TKTL1 transfectants.
In the latter, a strong additional signal around 65 kDa
representing the calculated size of full-length recombinant
TKTL1 protein [7] was detected, which was also described
by Bentz and coworkers previously [52].
The second anti-TKTL1 antibody used for Western blot
analysis was the monoclonal antibody clone 1C10 that de-
tected a distinct single TKTL1 protein with approximately
65 kDa in HEK293-TKTL1 transfectants, without the
additional protein bands seen with JFC12T10. Also,
polyclonal Sigma Prestige antibody did not recognize
additional proteins with different molecular weights in
any of the cell lines. The marginal signals in a few cell
lines seen with monoclonal 1C10 antibody most probably
represents unspecific background, which was eventually
similar in quality but inferior in quantity as compared to
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Prestige antibody detect exogenously expressed TKTL1
in a highly specific manner and as a protein of expectedly
65.4 kDa.
However, using a rabbit polyclonal antibody (Gene
Tex), Li et al. detected endogenous TKTL1 expression in
MCF-7 and HeLa cells by Western blot [53]. This result
is in contrast to our data, since none of the three tested
antibodies recognized TKTL1 protein in those cell lines.
This might reflect the different specificity of antibodies
and/or cell batches used. Likewise and in discordance to
our findings, Bentz et al. described cell line HT29 as
highly positive for TKTL1 protein expression in Western
blotting with antibody JFC12T10 [52]. Of note, Bentz
et al. used JFC12T10 in a remarkably high concentration
(diluted 1:100 compared to 1:2500 as in the present
work) and did not present any information about the
source of the cell line. Thus, the difference in the results
of Bentz as well as of Li to our findings despite using the
same cell lines underline the importance for an interla-
boratory cell identification screening program [57,58]. It
is worth to note, that numerous publications about
TKTL1 displayed small clippings of Western blot data
only and in some cases even the molecular weight
markers were omitted [11,28,53] or only one molecular
weight marker was given at 75 kDa [59]. These depictions
complicate the appraisal of results.
Similarly, immunohistochemistry analyses presented here
support a rather rare expression of TKTL1 protein in can-
cer and normal cell lines. In 2 out of 3 benign and 8 out of
17 malign cell lines tested in the present study, TKTL1 pro-
tein was detectable in the cytoplasm with the two anti-
bodies JFC12T10 and SigmaPrestige polyclonal antibody by
immunohistochemistry. For only one of these positively
stained cell lines (JAR) a weak expression of tktl1 mRNA
was detectable. Therefore JAR appears to be positive
for endogenous TKTL1 expression by RT-qPCR and
immunohistochemistry, however failed to be detected
by Western blot. The other cell line expressing tktl1
mRNA, U251, was positive in immunohistochemistry
with the JFC12T10 antibody only and also showed no
specific signal in Western blot.
In summary, two cell lines (JAR, and U251) were
found positive for both endogenous mRNA expression
as well as TKTL1 protein by immunohistochemistry with
one or two different anti-TKTL1 antibodies. Intriguingly,
these cell lines did neither exhibit an extraordinary
production of lactic acid at 21% oxygen in vitro
(Warburg effect) nor greater resistance against taxane
and cisplatin or ionizing radiation than cells without
clear TKTL1 detection. These findings are inconsistent
with the hypothesis of TKTL1 being a predictor of an
increased “Warburg effect” and special robustness of
tumor cells against chemotherapy and radiation in vitro.Conclusions
In this study we have demonstrated the necessity to
carefully prove TKTL1 expression on mRNA and protein
levels with multiple analytic tools (antibodies, primer
pairs) to identify cells with robust endogenous TKTL1
expression in vitro. TKTL1 expression emerged as a rather
rare event in cultured cell lines. The two out of 17 human
cancer cell lines JAR and U251, positive for tktl1 mRNA
and TKTL1 protein by immunohistochemistry and
Western blot for at least one antibody showed neither
an outstanding production of lactic acid nor increased
resistance against the chemotherapeutic drugs paclitaxel
and cisplatin or to ionizing radiation, respectively, com-
pared to the other cell lines.
Additional files
Additional file 1: Figure S1. Long time exposure of Western Blot. To
make the WB results comparable, we exposed the x-Ray film to an extent,
that the positive control cells (HEK293-TKTL1) resulted in a comparable
intensity of band signal at 65.4 kDa. The negative HEK293 control cells as
well as the tktl1 mRNA positive cell lines JAR and U251 were also shown.
Additional file 2: Table S1. Concentrations of glucose and lactate.
Mean and standard deviation is shown for glucose consumption and
lactate production of cell lines analyzed after 24 h of culture calculated
per 105 cells each. Summary of three independent experiments.
Abbreviations
ATP: Adenosine triphosphate; EC number: Enzyme Commission number;
PPP: Pentose phosphate pathway; RT-qPCR: Reverse transcriptase (RT)
quantitative polymerase chain reaction (qPCR); TKT: Transketolase;
TKTL1: Transketolase like enzyme 1.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
UK, NP, CO designed the study, performed the experiments, participated in
data collection, analysed and interpreted the results and drafted the
manuscript; UK, OG, CO contributed reagents, materials, and analytic tools;
NP, OG, AW, RJK revised the article for intellectual content and participated
in editorial support. All authors read and approved the final manuscript.
Acknowledgments
The authors are grateful to Michaela Kapp, Renate Bausch, and Monika
Koospal for their skilful assistance with the experiments; to Dr S. Leo,
KEYENCE INTERNATIONAL (Belgium) NV/SA, for kind technical support; to
PD Dr. Nikolas Schlegel, Department of General, Visceral, Vascular and
Paediatric Surgery, University Hospital of Würzburg, for the use of the
microscope. The work was supported by funds from the Interdisciplinary
Centre for Clinical Research (IZKF) of the University of Würzburg (A-169 to
UK, B-186 to AW, and D-150 to CO). The authors assume full responsibility
for the contents of the research. This publication was funded by the German
Research Foundation (DFG), and the University of Würzburg is in the funding
program “Open Access Publishing”.
Author details
1Department of Obstetrics and Gynaecology, University of Würzburg
Hospital, Josef-Schneider-Str. 4, D-97080 Würzburg, Germany. 2Department of
Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University,
Marchioninistr. 15, D-81377 Munich, Germany. 3present address: Apoptosis
and Tumour Metabolism Lab, CRUK Beatson Institute, Garscube Estate,
Switchback Road, Glasgow G61 1BD, United Kingdom. 4Department of
General, Visceral, Vascular and Paediatric Surgery, University Hospital of
Würzburg, Oberdürrbacher Str. 6, D-97080 Würzburg, Germany. 5Department
Kämmerer et al. BMC Cancer 2015, 15:2 Page 15 of 16
http://www.biomedcentral.com/1471-2407/15/2of Radiotherapy and Radiation Oncology, Leopoldina Hospital Schweinfurt,
Gustav-Adolf-Straße 8, D-97422 Schweinfurt, Germany. 6Experimental Surgery,
Experimental Transplantation Immunology, Department of General, Visceral,
Vascular and Paediatric Surgery, University Hospital of Würzburg,
Oberdürrbacher Str. 6, D-97080 Würzburg, Germany.
Received: 12 June 2014 Accepted: 27 November 2014
Published: 10 June 2015
References
1. Pontremoli S, Bonsignore A, Grazi E, Horecker BL: A coupled reaction
catalyzed by the enzymes transketolase and transaldolase. J Biol Chem
1960, 235:1881–1887.
2. Zhao J, Zhong CJ: A review on research progress of transketolase.
Neurosci Bull 2009, 25(2):94–99.
3. Schenk G, Duggleby RG, Nixon PF: Properties and functions of the thiamin
diphosphate dependent enzyme transketolase. Int J Biochem Cell Biol
1998, 30(12):1297–1318.
4. Ramos-Montoya A, Lee WN, Bassilian S, Lim S, Trebukhina RV, Kazhyna MV,
Ciudad CJ, Noé V, Centelles JJ, Cascante M: Pentose phosphate cycle
oxidative and nonoxidative balance: A new vulnerable target for
overcoming drug resistance in cancer. Int J Cancer 2006,
119(12):2733–2741.
5. Blass JP, Gibson GE: Abnormality of a thiamine-requiring enzyme in
patients with Wernicke-Korsakoff syndrome. N Engl J Med 1977,
297(25):1367–1370.
6. Coy JF, Dübel S, Kioschis P, Thomas K, Micklem G, Delius H, Poustka A:
Molecular cloning of tissue-specific transcripts of a transketolase-related
gene: implications for the evolution of new vertebrate genes.
Genomics 1996, 32(3):309–316.
7. Coy JF, Dressler D, Wilde J, Schubert P: Mutations in the transketolase-like
gene TKTL1: clinical implications for neurodegenerative diseases, diabetes
and cancer. Clin Lab 2005, 51(5–6):257–273.
8. Wittig R, Coy JF: The role of glucose metabolism and glucose-associated
signalling in cancer. Perspect Medicin Chem 2008, 1:64–82.
9. Smith IM, Glazer CA, Mithani SK, Ochs MF, Sun W, Bhan S, Vostrov A,
Abdullaev Z, Lobanenkov V, Gray A, Liu C, Chang SS, Ostrow KL, Westra WH,
Begum S, Dhara M, Califano J: Coordinated activation of candidate
proto-oncogenes and cancer testes antigens via promoter demethylation
in head and neck cancer and lung cancer. PLoS One 2009, 4(3):e4961.
10. Rolland AD, Lavigne R, Dauly C, Calvel P, Kervarrec C, Freour T, Evrard B,
Rioux-Leclercq N, Auger J, Pineau C: Identification of genital tract markers
in the human seminal plasma using an integrative genomics approach.
Hum Reprod 2013, 28(1):199–209.
11. Diaz-Moralli S, Tarrado-Castellarnau M, Alenda C, Castells A, Cascante M:
Transketolase-like 1 expression is modulated during colorectal cancer
progression and metastasis formation. PLoS One 2011, 6(9):e25323.
12. Földi M, Stickeler E, Bau L, Kretz O, Watermann D, Gitsch G, Kayser G,
Zur Hausen A, Coy JF: Transketolase protein TKTL1 overexpression:
A potential biomarker and therapeutic target in breast cancer. Oncol Rep
2007, 17(4):841–845.
13. Hu LH, Yang JH, Zhang DT, Zhang S, Wang L, Cai PC, Zheng JF, Huang JS:
The TKTL1 gene influences total transketolase activity and cell
proliferation in human colon cancer LoVo cells. Anticancer Drugs 2007,
18(4):427–433.
14. Schultz H, Kähler D, Branscheid D, Vollmer E, Zabel P, Goldmann T: TKTL1 is
overexpressed in a large portion of non-small cell lung cancer specimens.
Diagn Pathol 2008, 3:35.
15. Völker HU, Scheich M, Schmausser B, Kämmerer U, Eck M: Overexpression
of transketolase TKTL1 is associated with shorter survival in laryngeal
squamous cell carcinomas. Eur Arch Otorhinolaryngol 2007,
264(12):1431–1436.
16. Völker HU, Hagemann C, Coy J, Wittig R, Sommer S, Stojic J, Haubitz I,
Vince GH, Kämmerer U, Monoranu CM: Expression of transketolase-like 1
and activation of Akt in grade IV glioblastomas compared with grades II
and III astrocytic gliomas. Am J Clin Pathol 2008, 130(1):50–57.
17. Fröhlich E, Fink I, Wahl R: Is transketolase like 1 a target for the treatment
of differentiated thyroid carcinoma? A study on thyroid cancer cell lines.
Invest New Drugs 2009, 27(4):297–303.
18. Wu HT, Allie N, Myer L, Govender D: Anaplastic nephroblastomas express
transketolase-like enzyme 1. J Clin Pathol 2009, 62(5):460–463.19. Kayser G, Kassem A, Sienel W, Schulte-Uentrop L, Mattern D, Aumann K,
Stickeler E, Werner M, Passlick B, zur Hausen A: Lactate-dehydrogenase 5 is
overexpressed in non-small cell lung cancer and correlates with the
expression of the transketolase-like protein 1. Diagn Pathol 2010, 5:22.
20. Kayser G, Sienel W, Kubitz B, Mattern D, Stickeler E, Passlick B, Werner M,
Zur Hausen A: Poor outcome in primary non-small cell lung cancers is
predicted by transketolase TKTL1 expression. Pathology 2011, 43(7):719–724.
21. Hartmannsberger D, Mack B, Eggert C, Denzel S, Stepp H, Betz CS, Gires O:
Transketolase-like protein 1 confers resistance to serum withdrawal
in vitro. Cancer Lett 2011, 300(1):20–29.
22. Lange CA, Tisch-Rottensteiner J, Böhringer D, Martin G, Schwartzkopff J,
Auw-Haedrich C: Enhanced TKTL1 expression in malignant tumors of the
ocular adnexa predicts clinical outcome. Ophthalmology 2012,
119(9):1924–1929.
23. Langbein S, Zerilli M, Zur Hausen A, Staiger W, Rensch-Boschert K, Lukan N,
Popa J, Ternullo MP, Steidler A, Weiss C, Grobholz R, Willeke F, Alken P,
Stassi G, Schubert P, Coy JF: Expression of transketolase TKTL1 predicts
colon and urothelial cancer patient survival: Warburg effect reinterpreted.
Br J Cancer 2006, 94(4):578–585.
24. Zerilli M, Amato MC, Martorana A, Cabibi D, Coy JF, Cappello F, Pompei G,
Russo A, Giordano C, Rodolico V: Increased expression of transketolase-like-1
in papillary thyroid carcinomas smaller than 1.5 cm in diameter is
associated with lymph-node metastases. Cancer 2008, 113(5):936–944.
25. Warburg O, Minami S: Versuche an überlebendem Carzinom-Gewebe.
Klinische Wochenschr 1923, 2(17):776–777.
26. Warburg O: Über den Stoffwechsel der Carcinomzelle. Naturwissenschaften
1924, 12(50):1131–1137.
27. Gatenby RA, Gillies RJ: Why do cancers have high aerobic glycolysis?
Nat Rev Cancer 2004, 4(11):891–899.
28. Xu X, Zur Hausen A, Coy JF, Löchelt M: Transketolase-like protein 1
(TKTL1) is required for rapid cell growth and full viability of human
tumor cells. Int J Cancer 2009, 124(6):1330–1337.
29. Sun W, Liu Y, Glazer CA, Shao C, Bhan S, Demokan S, Zhao M, Rudek MA,
Ha PK, Califano JA: TKTL1 is activated by promoter hypomethylation and
contributes to head and neck squamous cell carcinoma carcinogenesis
through increased aerobic glycolysis and HIF1alpha stabilization.
Clin Cancer Res 2010, 16(3):857–866.
30. Langbein S, Frederiks WM, zur Hausen A, Popa J, Lehmann J, Weiss C,
Alken P, Coy JF: Metastasis is promoted by a bioenergetic switch: new targets
for progressive renal cell cancer. Int J Cancer 2008, 122(11):2422–2428.
31. Mitschke L, Parthier C, Schröder-Tittmann K, Coy J, Lüdtke S, Tittmann K:
The crystal structure of human transketolase and new insights into its
mode of action. J Biol Chem 2010, 285(41):31559–31570.
32. Maslova AO, Meshalkina LE, Kochetov GA: Computer modeling of
transketolase-like protein, TKTL1, a marker of certain tumor tissues.
Biochemistry (Mosc) 2012, 77(3):296–299.
33. Schneider S, Lüdtke S, Schröder-Tittmann K, Wechsler C, Meyer D, Tittmann K: A
δ38 deletion variant of human transketolase as a model of transketolase-like
protein 1 exhibits no enzymatic activity. PLoS One 2012, 7(10):e48321.
34. Meshalkina LE, Drutsa VL, Koroleva ON, Solovjeva ON, Kochetov GA: Is
transketolase-like protein, TKTL1, transketolase? Biochim Biophys Acta
2013, 1832(3):387–390.
35. Schwaab J, Horisberger K, Ströbel P, Bohn B, Gencer D, Kähler G, Kienle P,
Post S, Wenz F, Hofmann WK, Hofheinz RD, Erben P: Expression of Transketolase
like gene 1 (TKTL1) predicts disease-free survival in patients with locally
advanced rectal cancer receiving neoadjuvant chemoradiotherapy.
BMC Cancer 2011, 11:363.
36. Fenske W, Völker HU, Adam P, Hahner S, Johanssen S, Wortmann S,
Schmidt M, Morcos M, Müller-Hermelink HK, Allolio B, Fassnacht M: Glucose
transporter GLUT1 expression is an stage-independent predictor of
clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer 2009,
16(3):919–928.
37. Schmidt M, Voelker HU, Kapp M, Krockenberger M, Dietl J, Kammerer U:
Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of
GLUT1, TKTL1 and down-regulation of M2PK. J Cancer Res Clin Oncol 2010,
136(2):219–225.
38. Fritz P, Coy JF, Mürdter TE, Ott G, Alscher MD, Friedel G: TKTL-1 expression
in lung cancer. Pathol Res Pract 2012, 208(4):203–209.
39. Honig A, Rieger L, Kapp M, Dietl J, Kämmerer U: Immunohistochemistry in
human placental tissue–pitfalls of antigen detection. J Histochem Cytochem
2005, 53(11):1413–1420.
Kämmerer et al. BMC Cancer 2015, 15:2 Page 16 of 16
http://www.biomedcentral.com/1471-2407/15/240. Krockenberger M, Honig A, Rieger L, Coy JF, Sutterlin M, Kapp M, Horn E,
Dietl J, Kammerer U: Transketolase-like 1 expression correlates with
subtypes of ovarian cancer and the presence of distant metastases.
Int J Gynecol Cancer 2007, 17(1):101–106.
41. Krockenberger M, Engel JB, Schmidt M, Kohrenhagen N, Häusler SF,
Dombrowski Y, Kapp M, Dietl J, Honig A: Expression of transketolase-like 1
protein (TKTL1) in human endometrial cancer. Anticancer Res 2010,
30(5):1653–1659.
42. Schmidt M, Kammerer U, Segerer S, Cramer A, Kohrenhagen N, Dietl J,
Voelker HU: Glucose metabolism and angiogenesis in granulosa cell
tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and
VEGF. Eur J Obstet Gynecol Reprod Biol 2008, 139(1):72–78.
43. Kohrenhagen N, Voelker HU, Schmidt M, Kapp M, Krockenberger M,
Frambach T, Dietl J, Kammerer U: Expression of transketolase-like 1
(TKTL1) and p-Akt correlates with the progression of cervical neoplasia.
J Obstet Gynaecol Res 2008, 34(3):293–300.
44. Bradford MM: A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
binding. Anal Biochem 1976, 72:248–254.
45. Haas J-P: Home made ECL Labjournal. 2005, http://www.laborjournal.de/
rubric/tricks/tricks/trick81.lasso.
46. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A,
Speleman F: Accurate normalization of real-time quantitative RT-PCR data
by geometric averaging of multiple internal control genes. Genome Biol
2002, 3(7):RESEARCH0034.
47. Pfaffl MW: A new mathematical model for relative quantification in
real-time RT-PCR. Nucleic Acids Res 2001, 29(9):e45.
48. Kueng W, Silber E, Eppenberger U: Quantification of cells cultured on
96-well plates. Anal Biochem 1989, 182(1):16–19.
49. Alberts DS, Chen HSG, Salmon SE, Survit EA, Young L, Moon TE, Meyskens FL Jr:
Chemotherapy of ovarian cancer directed by the human tumor stem cell
assay. Cancer Chemother Pharmacol 1981, 6:279–285.
50. Metzger R, Deglmann CJ, Hoerrlein S, Zapf S, Hilfrich J: Towards in-vitro
prediction of an in-vivo cytostatic response of human tumor cells with
a fast chemosensitivity assay. Toxicology 2001, 166(1–2):97–108.
51. Staiger WI, Coy JF, Grobholz R, Hofheinz RD, Lukan N, Post S, Schwarzbach MH,
Willeke F: Expression of the mutated transketolase TKTL1, a molecular
marker in gastric cancer. Oncol Rep 2006, 16(4):657–661.
52. Bentz S, Cee A, Endlicher E, Wojtal KA, Naami A, Pesch T, Lang S, Schubert P,
Fried M, Weber A, Coy JF, Goelder S, Knüchel R, Hausmann M, Rogler G:
Hypoxia induces the expression of transketolase-like 1 in human colorectal
cancer. Digestion 2013, 88(3):182–192.
53. Li B, Iglesias-Pedraz JM, Chen LY, Yin F, Cadenas E, Reddy S, Comai L:
Downregulation of the Werner syndrome protein induces a metabolic
shift thatcompromises redox homeostasis and limits proliferation of
cancer cells. Aging Cell 2014, 13(2):367–378.
54. Mayer A, Von Wallbrunn A, Vaupel P: Glucose metabolism of malignant
cells is not regulated by transketolase-like (TKTL)-1. Int J Oncol 2010,
37(2):265–271.
55. Grimm M, Schmitt S, Teriete P, Biegner T, Stenzl A, Hennenlotter J, Muhs HJ,
Munz A, Nadtotschi T, König K, Sänger J, Feyen O, Hofmann H, Reinert S,
Coy JF: A biomarker based detection and characterization of carcinomas
exploiting two fundamental biophysical mechanisms in mammalian
cells. BMC Cancer 2013, 13:569.
56. Chen H, Yue JX, Yang SH, Ding H, Zhao RW, Zhang S: Overexpression of
transketolase-like gene 1 is associated with cell proliferation in uterine
cervix cancer. J Exp Clin Cancer Res 2009, 28:43.
57. Chatterjee R: Cell biology. Cases of mistaken identity. Science 2007,
315(5814):928–931.
58. Chatterjee R: Cell biology. When 60 lines don’t add up. Science 2007b,
315(5814):929.
59. Yuan W, Wu S, Guo J, Chen Z, Ge J, Yang P, Hu B, Chen Z: Silencing of
TKTL1 by siRNA inhibits proliferation of human gastric cancer cells
in vitro and in vivo. Cancer Biol Ther 2010, 9(9):710–716.
60. Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE: Heterogeneity
of malignant cells from a human colonic carcinoma. Cancer Res 1981,
41(5):1751–1756.
61. Thalheimer A, Korb D, Boenicke L, Wiegering A, Muehling B, Schneider M,
Koch S, Riedel S, Germer C-T, Braendlein S, Otto C: Non-invasive visualisation
of tumour growth in a human colorectal liver metastases xenograft model
using Bioluminescence in vivo Imaging. J Surg Res 2013, 195(1):143–151.62. Gey GO, Coffman WD, Kubicek MT: Tissue culture studies of the
proliferative capacity of cervical carcinoma and normal epithelium.
Cancer Res 1952, 12:264.
63. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB: Controlled synthesis
of HBsAg in a differentiated human liver carcinoma-derived cell line.
Nature 1979, 282(5739):615–616.
64. Fogh J, Wright WC, Loveless JD: Absence of HeLa cell contamination in 169
cell lines derived from human tumors. J Natl Cancer Inst 1977, 58(2):209–214.
65. Pattillo RA, Ruckert A, Hussa R, Bernstein R, Delfs E: The JAR cell line - continous
human multihormone production and controls. In Vitro 1971, 6:398–399.
66. Kohler PO, Bridson WE: Isolation of hormone-producing clonal lines of human
choriocarcinoma. J Clin Endocrinol Metab 1971, 32:683–687.
67. Vollmers HP, Stulle K, Dämmrich J, Pfaff M, Papadopoulos T, Betz C, Saal K,
Müller-Hermelink HK: Characterization of four new gastric cancer cell
lines. Virchows Arch B Cell Pathol Incl Mol Pathol 1993, 63(6):335–343.
68. Illert B, Otto C, Braendlein S, Thiede A, Timmermann W: Optimization of a
metastasizing human gastric cancer model in nude mice.
Microsurgery 2003, 23(5):508–512.
69. Soule HD, Vazguez J, Long A, Albert S, Brennan M: A human cell line from
a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst
1973, 51(5):1409–1416.
70. Cailleau R, Young R, Olivé M, Reeves WJ Jr: Breast tumor cell lines from
pleural effusions. J Natl Cancer Inst 1974, 53:661–674.
71. Bruggen J, Fogh J, Sorg C: Tumor production in the nude mouse, fibrinolytic
activity and cross- reactivity with antimelanoma sera of various human
tumor cell lines. J Cancer Res Clin Oncol 1981, 102:141–152.
72. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW,
Whang-Peng J, Rogan AM, Green WR, Ozols RF: Characterization of a human
ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen
receptors. Cancer Res 1983, 43(11):5379–5389.
73. Zeuthen J, Nørgaard JO, Avner P, Fellous M, Wartiovaara J, Vaheri A, Rosén A,
Giovanella BC: Characterization of a human ovarian teratocarcinoma-derived
cell line. Int J Cancer 1980, 25(1):19–32.
74. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM:
Structural and transcriptional analysis of human papillomavirus type 16
sequences in cervical carcinoma cell lines. J Virol 1987, 61:962–971.
75. Pontén J, Macintyre EH: Long term culture of normal and neoplastic
human glia. Acta Pathol Microbiol Scand 1968, 74(4):465–486.
76. Petricciani JC, Wallace RE, McCoy DW: A comparison of three in vivo
assays for cell tumorigenicity. Cancer Res 1974, 34(1):105–108.
77. Corfield VA, Hay RJ: Effects of cystine or glutamine restriction on human
diploid fibroblasts in culture. In Vitro 1978, 14:787–794.
doi:10.1186/1471-2407-15-2
Cite this article as: Kämmerer et al.: TKTL1 expression in human malign
and benign cell lines. BMC Cancer 2015 15:2.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
